Merck & Co., Inc. (MRK) Debt to Equity Ratio: 0.96
Is Merck & Co., Inc.’s debt to equity ratio high or low?
Merck & Co., Inc.'s debt to equity ratio of 0.96 is in line with its 5-year average of 0.95, around the middle of its 5-year range (0.70–1.32).
As of Thursday, June 11, 2026. 7.26% above its 12-month average of 0.90.
MRK Debt to Equity Ratio Chart
MRK Average Debt to Equity Ratio Chart
MRK Current vs Average Debt to Equity Ratio Chart
MRK Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.96
DEBT TO EQUITY RATIO AVG TTM
0.90
DEBT TO EQUITY RATIO AVG 3Y
0.86
DEBT TO EQUITY RATIO AVG 5Y
0.95
DEBT TO EQUITY RATIO AVG 10Y
0.87
DEBT TO EQUITY RATIO AVG 15Y
0.72
DEBT TO EQUITY RATIO AVG 20Y
0.64
CURRENT VS TTM AVG
+7.26%
CURRENT VS 3Y AVG
+10.98%
CURRENT VS 5Y AVG
+1.23%
CURRENT VS 10Y AVG
+9.89%
CURRENT VS 15Y AVG
+32.53%
CURRENT VS 20Y AVG
+50.67%
MRK Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $298.23B | 0.96 | 0.90 | 0.86 | 0.95 |
| AstraZeneca PLC (AZN) | $282.69B | 0.61 | 0.68 | 0.72 | 0.83 |
| UnitedHealth Group Incorporated (UNH) | $369.16B | 0.83 | 0.83 | 0.79 | 0.74 |
| AbbVie Inc. (ABBV) | $399.86B | -21.12 | 13.10 | 8.74 | 8.32 |
| Amgen Inc. (AMGN) | $188.37B | 6.31 | 8.27 | 9.39 | 7.67 |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 0.76 | 0.71 | 0.76 | 0.76 |
| Gilead Sciences, Inc. (GILD) | $156.35B | 1.09 | 1.23 | 1.19 | 1.29 |
| Abbott Laboratories (ABT) | $155.75B | 0.29 | 0.30 | 0.38 | 0.44 |
| Pfizer Inc. (PFE) | $149.61B | 0.78 | 0.77 | 0.68 | 0.63 |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 0.02 | 0.01 | 0.01 | 0.01 |
Financial Health
Debt/Equity
0.96
Current Ratio
1.54
Merck & Co., Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Merck & Co., Inc. (MRK)?
- The debt to equity ratio for MRK stock is 0.96.
- Is Merck & Co., Inc.'s debt to equity ratio high or low?
- Merck & Co., Inc.'s debt to equity ratio of 0.96 is in line with its 5-year average of 0.95, around the middle of its 5-year range (0.70–1.32).
- What is the TTM average debt to equity ratio for Merck & Co., Inc. (MRK)?
- The TTM average debt to equity ratio for MRK stock is 0.90.
- What is the 3Y average debt to equity ratio for Merck & Co., Inc. (MRK)?
- The 3Y average debt to equity ratio for MRK stock is 0.86.
- What is the 5Y average debt to equity ratio for Merck & Co., Inc. (MRK)?
- The 5Y average debt to equity ratio for MRK stock is 0.95.
- What is the 10Y average debt to equity ratio for Merck & Co., Inc. (MRK)?
- The 10Y average debt to equity ratio for MRK stock is 0.87.
- What is the 15Y average debt to equity ratio for Merck & Co., Inc. (MRK)?
- The 15Y average debt to equity ratio for MRK stock is 0.72.
- What is the 20Y average debt to equity ratio for Merck & Co., Inc. (MRK)?
- The 20Y average debt to equity ratio for MRK stock is 0.64.
Merck & Co., Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.96 |
| 2024-12-31 | 0.83 |
| 2023-12-31 | 0.97 |
| 2022-12-31 | 0.70 |
| 2021-12-31 | 0.91 |
| 2020-12-31 | 1.32 |
| 2019-12-31 | 1.06 |
| 2018-12-31 | 0.94 |
| 2017-12-31 | 0.71 |
| 2016-12-31 | 0.62 |
| 2015-12-31 | 0.59 |
| 2014-12-31 | 0.44 |
| 2013-12-31 | 0.50 |
| 2012-12-31 | 0.39 |
| 2011-12-31 | 0.32 |
| 2010-12-31 | 0.33 |
| 2009-12-31 | 0.30 |
| 2008-12-31 | 0.33 |
| 2007-12-31 | 0.32 |
| 2006-12-31 | 0.39 |
| 2005-12-31 | 0.45 |
| 2004-12-31 | 0.40 |
| 2003-12-31 | 0.44 |
| 2002-12-31 | 0.47 |
| 2001-12-31 | 0.55 |
| 2000-12-31 | 0.47 |
| 1999-12-31 | 0.45 |
| 1998-12-31 | 0.30 |
| 1997-12-31 | 0.18 |
| 1996-12-31 | 0.15 |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis